In human mammary and prostate cancer cells, steroid hormones or epidermal growth factor (EGF) trigger association of the androgen receptor (AR)-estradiol receptor (ER) (a or b) complex with Src. This interaction activates Src and affects the G1 to S cell cycle progression. In this report, we identify the sequence responsible for the AR/Src interaction and describe a 10 amino-acid peptide that inhibits this interaction. Treatment of the human prostate or mammary cancer cells (LNCaP or MCF-7, respectively) with nanomolar concentrations of this peptide inhibits the androgen-or estradiol-induced association between the AR or the ER and Src the Src/Erk pathway activation, cyclin D1 expression and DNA synthesis, without interfering in the receptor-dependent transcriptional activity. Similarly, the peptide prevents the S phase entry of LNCaP and MCF-7 cells treated with EGF as well as mouse embryo fibroblasts stimulated with androgen or EGF. Interestingly, the peptide does not inhibit the S phase entry and cytoskeletal changes induced by EGF or serum treatment of AR-negative prostate cancer cell lines. The peptide is the first example of a specific inhibitor of steroid receptordependent signal transducing activity. The importance of these results is highlighted by the finding that the peptide strongly inhibits the growth of LNCaP xenografts established in nude mice.
In human mammary and prostate cancer cells, steroid hormones or epidermal growth factor (EGF) trigger association of the androgen receptor (AR)-estradiol receptor (ER) (a or b) complex with Src. This interaction activates Src and affects the G1 to S cell cycle progression. In this report, we identify the sequence responsible for the AR/Src interaction and describe a 10 amino-acid peptide that inhibits this interaction. Treatment of the human prostate or mammary cancer cells (LNCaP or MCF-7, respectively) with nanomolar concentrations of this peptide inhibits the androgen-or estradiol-induced association between the AR or the ER and Src the Src/Erk pathway activation, cyclin D1 expression and DNA synthesis, without interfering in the receptor-dependent transcriptional activity. Similarly, the peptide prevents the S phase entry of LNCaP and MCF-7 cells treated with EGF as well as mouse embryo fibroblasts stimulated with androgen or EGF. Interestingly, the peptide does not inhibit the S phase entry and cytoskeletal changes induced by EGF or serum treatment of AR-negative prostate cancer cell lines. The peptide is the first example of a specific inhibitor of steroid receptordependent signal transducing activity. The importance of these results is highlighted by the finding that the peptide strongly inhibits the growth of LNCaP xenografts established in nude mice.
Introduction
Prostate and mammary cancers are among the most frequently diagnosed cancers and are major causes of cancer death. These cancers are frequently androgen receptor (AR) positive (Lopez-Otin and Diamandis, 1998) , and express the a-or b-forms of the estradiol receptor (ER). AR and ER expression is maintained even in hormone-independent cancers, although their role under these conditions is still poorly understood. More than 80% of clinically androgen independent human prostate tumors show high levels of AR (Zhao et al., 2000) . There appear to be different possible mechanisms for acquiring androgen-independence in the presence of AR expression. An increased level of AR could sensitize cancers to low levels of residual androgens, and antiandrogens could promote androgen activation rather than inhibition (Chen et al., 2004) . Also, growth factors, such as epidermal growth factor (EGF), could bypass the hormone requirement by directly activating the AR (Culig et al., 1994 , Migliaccio et al., 2005 . Alternatively, non-androgenic steroids could promote androgen-independent growth of prostate cancer cells through a mutated AR (Zhao et al., 2000) . Estrogen independence in the presence of ER might arise via other mechanisms including the ligandindependent ER activation, expression of ER variants, and increased expression of co-activators (Gururaj et al., 2006) . In addition, alteration of the complex interactions between ER and membrane-associated or cytoplasmic effectors might be involved in breast tumor progression as well as resistance to hormonal therapy (Vadlamudi et al., 2005) .
Previous studies have shown that sex steroid hormones activate signal transducing pathways that are frequently upregulated in human breast tumors (Cato et al., 2002; Levin, 2003) . In human prostate and mammary cancer-derived cells, treatment with androgen or estrogen rapidly induces association of Src with AR and ER, leading to Src activation and stimulation of DNA synthesis (Migliaccio et al., 2000) . AR association with Src has also been observed in androgen-stimulated immortalized fibroblasts (Castoria et al., 2003) , raising the possibility that, in response to androgens, stromal cells facilitate the malignant outgrowth and the metastatic spread of prostate epithelial cells. In addition, EGF signaling, which induces S phase entry and cytoskeletal changes of prostate and breast cancer cells, requires AR/ER association with Src (Migliaccio et al., 2005) .
On the basis of our previous findings (Migliaccio et al., 2000) and establishment of new functional assays for AR deletion mutants, in this report, we define the amino-acid sequence responsible for the human AR (hAR) interaction with Src. A synthetic 10 amino-acid peptide that mimics this sequence prevents the AR/ER complex from associating with Src. This peptide inhibits the G1 to S transition of androgen-or estradiolstimulated prostate and mammary cancer cells in vitro as well as the growth of LNCaP prostate cell xenografts established in nude mice. Because of the role of AR in EGF-elicited signaling (Migliaccio et al., 2005) , the peptide also prevents EGF-dependent DNA synthesis in normal and cancer cell lines. Use of this peptide, alone or in association with other compounds, potentially offers a novel approach to specifically inhibit human prostate and breast cancers.
Results
Deletion of the 371-422 sequence of the hAR abolishes the in vitro association of the receptor with the Src SH3 domain (Migliaccio et al., 2000) . To better define the AR-interacting sequence, different human AR-deletion mutants were prepared. Three deletions were separately introduced within the proline-rich 372-379 region and the contiguous sequence including arginine ( Figure 1a ). Arginine is either contiguous or adjacent to proline in Src, Yes and Lyn SH3-binding peptides (Kay et al., 2000) . The wild-type (wt) AR and its three mutants were transiently transfected in Cos cells, which do not express endogenous AR, and the ectopically expressed AR was detected by immunoblotting the cell lysates with an anti-AR antibody (Figure 1b, upper panel) . To assess the interaction of Src with AR, lysates from Cos cells treated with the synthetic androgen R1881 for 3 min were incubated with anti-Src antibodies and the immunocomplexes blotted with antibodies against either Src or AR. In the presence of the synthetic androgen R1881, a strong association of wt AR with Src was detected, whereas a much weaker association, similar to that found in the absence of hormone, was observed in cells expressing the AR mutants (Figure 1b , lower panel). As expected (Migliaccio et al., 2000) , Src immunoprecipitated with the wt AR from the lysate of Cos cells treated with R1881 for 3 min actively phosphorylated acidified enolase. In contrast, no increase of Src activity over the basal level was observed when the AR constructs with a deletion of either the 372-385 residues (ARÀD1) or the 372-378 sequence (ARÀD2) were overexpressed in the same cells (Figure 1c) . The AR deleted of the 380-386 (ARÀD3) sequence only weakly activated Src (Figure 1c) .
In contrast to Src activation, Cos cells transfected with the deleted AR did not show reduction of ARdependent gene transcription. To verify this issue, an androgen enhancer (the 3416 construct; Verrijdt et al., 2000) was transiently co-transfected in Cos cells and the effect of R1881 on reporter gene transcription was evaluated (Figure 1d ).
To characterize further the functional role of the AR proline-rich region, four peptides derived from the sequences deleted in the AR mutants were chemically synthesized. The peptides were N-terminal acetylated and C-terminal amidated (Figure 2 , upper panel). They were analysed for the ability to reduce the DNA synthesis induced by R1881 in LNCaP (Figure 2 , middle panel) or estradiol in MCF-7 (Figure 2 , lower panel) cells. A peptide corresponding to the amino acids 377-386 of the hAR (Ac-PPPHPHARIK-NH2; S1 peptide) was finally selected because of its slightly stronger inhibitory action and its smaller size. In addition, a peptide containing the same amino-acid composition of the S1 peptide, but with a shuffled sequence (Ac-HPKPARIPHP-NH2) was synthesized (Ss peptide) and analysed in parallel. The uptake of both carboxyfluorescein-conjugated S1 and Ss peptides was firstly analysed by confocal microscopy in quiescent, unfixed LNCaP cells. Figure 3a shows that in 30 min at 371C the peptides are delivered similarly into the cells (upper panels). No dependence on the temperature was observed, thus excluding an energy-dependent mechanism of peptide internalization (lower panels in Figure 3a ). Similar results were obtained in fixed LNCaP cells (not shown). To assess the effect of the peptides on association between Src and AR, or ER, we used quiescent LNCaP and MCF-7 cells. As expected, R1881 or estradiol triggered the interaction of the corresponding receptor with Src in LNCaP or MCF-7 cells, respectively, (Figure 3b and c, upper panels). Notably, treatment of these cells with the S1 peptide or the steroid antagonists Casodex (Figure 3b ) or ICI 182 780 (Figure 3c ) prevented the receptor/Src interaction (Figure 3b and c, upper panels). The Ss peptide did not abolish the hormonal-induced assembly of Src with AR or ER, although a decrease of the complex assembly was observed. The S1 peptide also prevented the hormonal activation of Src and Erk assayed as enolase (en) and myelin basic protein (MBP) phosphorylation, respectively. Such an effect supports the evidence that the S1 peptide action on the association of the steroid receptors with Src is responsible for the inhibition of the mitogenic Src/Erk pathway triggered by hormones. The Ss peptide effect on the activity of Src and Erk is negligible or absent (Figure 3b and c, upper and lower panels).
In agreement with our previous findings (Castoria et al., 2001) , LNCaP or MCF-7 cells treated with R1881 or estradiol for 8 h show an increase in cyclin D1 expression and the Src-kinase inhibitor, PP2, abolished this hormonal effect (Figure 4a and c) . The increased expression of cyclin D1 was clearly prevented by the S1 peptide and slightly decreased by the Ss peptide (Figure 4a and c) . At this point it is clear that the S1 peptide prevents an entire sequence of events: AR/Src association, Src/Erk activation, cyclin-D1 expression. This conclusion suggested that AR/Src interaction might be a target for inhibition of the AR/Srcdependent cell proliferation by this peptide. Such a possibility was verified by treating LNCaP or MCF-7 cells with either R1881 or estradiol (Figure 4b and d) , in the presence or absence of the corresponding steroid antagonists and comparing the inhibitory response to that observed in the presence of the peptide. The S1 peptide and the steroid antagonists inhibited to a similar extent DNA synthesis in LNCaP and MCF-7 cells, whereas the scrambled peptide slightly reduced the hormonal effect.
It has been recently reported that, in LNCaP and MCF-7 cells, EGF-induced signaling requires the association of AR and ER with Src (Migliaccio et al., 2005) . In addition, AR or ER inhibition by steroid antagonists or siRNA prevents EGF-triggered DNA synthesis and cytoskeletal changes (Migliaccio et al., 2005) . This is confirmed by the experiments in Figure 5 showing that steroid antagonists inhibit EGF-induced DNA synthesis in LNCaP and MCF-7 cells. Interestingly, the S1 peptide also abolished the EGF effect in these cells, whereas the Ss peptide had no effect (Figure 5a and b). Since the NIH3T3 fibroblasts express AR (Castoria et al., 2003) , the effect of the S1 peptide on the S phase entry of NIH3T3 fibroblasts stimulated with R1881 or EGF was also evaluated (Figure 5c ). The S1 peptide substantially reduced the R1881-and EGFinduced DNA synthesis in NIH3T3 fibroblasts, while the Ss peptide showed again little or no effect ( Figure 5c ). Experiments in Figure 6a show that serum-induced DNA synthesis in NIH3T3 fibroblasts, LNCaP or MCF-7 cells is unaffected by the S1 peptide, thus implicating that the inhibitory effect of the peptide is restricted to AR-dependent DNA synthesis. This conclusion is further reinforced by data in panels b and c , cells were made quiescent and then left untreated or treated for 3 min with 10 nM R1881. In (b), lysates were either analysed for expression of AR and its mutants using the anti-AR antibody (upper panel) or immunoprecipitated with anti-Src MAb (lower panels). Immunocomplexes were then immunoblotted with the antibodies against the proteins indicated by the arrows. In (c), lysates were immunoprecipitated with the anti-Src MAb and the Src kinase activity assayed using acidified enolase as a substrate (lower panel). Immunocomplexes were also blotted with the anti-Src MAb to control the protein loading (upper panel). In (d), cells were co-transfected along with ARE3416 construct, then left unstimulated or stimulated for 18 h with 10 nM R1881. The luciferase activity was assayed, normalized using b-gal as internal control and expressed as fold induction. Wt, wild-type.
A new androgen receptor antagonist A Migliaccio et al of the same figure, showing that addition of the S1 peptide does not affect EGF or serum-induced DNA synthesis of AR-negative PC3 or DU145 cells. Another finding against the possibility that the effect of the S1 peptide is due to interference in intrinsic Src activity is shown in Figure 6d . Clearly, the peptide has no effect on a typical Src-dependent effect, such as the cytoskeletal changes in EGF-treated DU 145 cells. In contrast, the Src inhibitor PP2 completely abolishes the induction of fan-like protrusions by EGF (Figure 6d ). These data together with previous results clearly demonstrate that the S1-peptide specifically targets Src activation dependent on AR, but does not affect the intrinsic activity of this kinase.
The effect of the S1 peptide on steroid receptordependent transcription was then analysed. Therefore, the stimulatory effect of R1881 on the AR-dependent transcriptional activity in LNCaP cells transfected with an ARE-luciferase gene reporter (Figure 7a ) and the The 30 min uptake of fluorescein-conjugated S1 or Ss (upper microphotographs) peptides in quiescent, unfixed LNCaP cells analysed by confocal microscopy is shown. Lower images of (a) show the fluorescent conjugated S1 peptide incubated at 41C (left microphotograph) or 371C (right microphotograph). In (b), quiescent LNCaP cells were left unstimulated or challenged for 3 min with 10 nM R1881, in the absence or presence of the indicated compounds. The antiandrogen Casodex (Cdx) was used at 10 mM, whereas the S1 (S1) and the shuffled (Ss) peptides were used at 1 nM. In (c), quiescent MCF-7 cells were left unstimulated or stimulated for 3 min with 10 nM estradiol in the absence or presence of the indicated compounds. The antiestrogen ICI (ICI) was used at 10 mM; the S1 (S1) and the shuffled (Ss) peptides were used at 1 nM. Lysates in (b and c) were immunoprecipitated with either anti-Src MAb (upper panels) or anti-Erk-2 Ab (lower panels). In the upper panels, immunocomplexes were either blotted with antibodies against the proteins indicated by the arrows or assayed for Src activity, using enolase as a substrate (en). In the lower panels, immunocomplexes were either blotted with anti-Erk-2 antibody, or assayed for Erk-2 activity using MBP as a substrate. AR, androgen receptor; ER, estradiol receptor; MBP, myelin basic protein.
A new androgen receptor antagonist
A Migliaccio et al estradiol effect on the ER transcriptional activity in MCF-7 cells transfected with an ERE-luciferase gene reporter ( Figure 7b ) were examined. In contrast with classic androgen (Casodex) or estradiol (ICI) antagonists, the S1 or the Ss peptide did not significantly affect the hormonal action in both cell lines. This supports the view that the S1 peptide inhibits only the non-genomic action of AR or ER on DNA synthesis but has no effect on transcriptional activation mediated by these receptors. Next, we analysed the effect of the S1 peptide on LNCaP xenografts established in nude mice. Interestingly, treatment with S1 peptide strongly inhibited tumor growth of LNCaP cells, whereas a negligible effect was observed upon treatment with the Ss peptide (Figure 8a ). At the conclusion of the experiments, tumor tissues were analysed by immunohistochemistry for cell proliferation and apoptotic index. The proliferation status of cancer cells was determined by Ki67 positivity, which was significantly decreased (Po0.005) in LNCaP tumors treated with the S1 peptide ( Figure 8b and C 2 ). In addition, the number of terminal deoxynucleotidyl transferase biotin-dUTP nick end labeling (TUNEL)-positive nuclei was also significantly increased (Po0.001) in the same tumors ( Figure 8b and 8d 2 ), indicating that the peptide treatment acts on both proliferation and apoptosis. The peptide-treated mice did not show a decrease in weight (not shown).
Discussion
The current therapy of prostate and mammary cancers is based on the use of steroid antagonists. However, this approach is limited by the mixed, antagonist and agonist action of these molecules, their side effects, and the appearance of hormone resistance. Estradiol, progestins and androgens induce G1 to S transition of cells derived from human mammary and prostate cancers through activation of signal transducing pathways (Castoria et al., 1999; Migliaccio et al., 2000) . These findings open potential new approaches to the therapy of hormonedependent cancers. In principle, such new therapy could be more specific than the classical therapy with steroid antagonists. This is because the classic antagonists, in addition to abolish the receptor-dependent signaling pathways, also inhibit the receptor transcriptional action. This action is not required for the steroidstimulated DNA synthesis of mammary and prostate cancer-derived cells in vitro (Castoria et al., 1999; Migliaccio et al., 2000) but is relevant to positive actions of sex-steroid hormones, such as neuroprotection and bone preservation.
Simultaneous ER and AR association with Src is the initial event triggered during sex steroid-induced G1 to S transition of MCF-7 and LNCaP cells (Migliaccio et al., 2000) . The same association is required in the same cells for EGF-induced DNA synthesis (Migliaccio et al., 2005) . Recent work indicates that association of the two A new androgen receptor antagonist A Migliaccio et al receptors with Src in response to a single signal is due to the presence of an ER/AR complex in unstimulated mammary and prostate cancer-derived cells (Migliaccio et al., 2005) . Therefore, a single steroid antagonist (antiestrogen or antiandrogen) can equally block the androgen or the estradiol-induced association of the ER/AR complex with Src (Migliaccio et al., 2000 (Migliaccio et al., , 2005 . Because of the crucial role of receptor/Src interaction in steroid-or growth factor-triggered cell proliferation (Migliaccio et al., 2000 (Migliaccio et al., , 2005 , we speculated that this association might be a target for specific anticancer drugs. These drugs, in contrast to general signal transducing inhibitors, should spare signal-transducing pathways not involved in the steroid receptor action. Parallel use of deletion AR mutants and synthetic peptides mirroring the deleted sequences in functional assays show that the entire 372-379 proline stretch or a part of it and the adjacent sequence including the arginine amino acid plays an important role in the AR/ Src association. Use of the S1 peptide directly proves the link between the association, Src/Erk activation, cyclin D1 expression and the S phase entry. Similar concentrations of a peptide with the same composition but a shuffled sequence show a weak inhibition of the same processes suggesting that, although many peptides containing prolines might be slightly inhibitory, only peptides exactly repeating the AR proline-rich sequence can exert a strong negative effect. Remarkably, experiments in AR-negative cells stimulated by EGF show that the peptide does not interfere in the DNA synthesis.
In the same cells, EGF-induced cytoskeletal changes, which also depend on Src activity, are unaffected by the peptide. These data show that AR is required for the observed inhibitory effects of the peptide treatment. Furthermore, the steroid receptor-dependent transcriptional activity is unaffected by the peptide. All together, these findings show that this compound is a specific antagonist of the signaling activation dependent on steroid receptors. NIH3T3 cells as well as mouse embryo or mouse female adult fibroblasts express a very low amount of AR (Castoria et al., 2003) . This receptor mediates a robust DNA synthesis induced by androgens in these cells. Such a response also requires AR/Src association and Src activation. Interestingly, NIH3T3 cells, unlike the mammary and prostate cancer cells, do not respond to androgen with receptor dependent transcriptional activity. Therefore, they represent a model useful for the analysis of receptor antagonist action independently of the receptor transcriptional activity. We are additionally interested in these cells since stromal cells, through a cross talk with epithelial cells, have a role in the development and carcinogenesis of both the prostate and the mammary gland (Coussens and Werb, 2002; Cunha et al., 2002) . For this reason, interference of the inhibitory peptide in AR/Src complex assembled upon androgen or growth factor stimulation of fibroblasts might also affect the interactions between stromal and epithelial cells, and in such a way contribute to slow down cancer growth. The ability of the peptide to inhibit the G1 to S transition of NIH3T3 fibroblasts stimulated by androgen is additional evidence that this inhibitory effect does not require the receptor transcriptional activity.
Furthermore, the S1 peptide inhibits DNA synthesis induced by EGF in prostate and breast cancer cells. This is an important point, since many human malignancies express high levels of growth factors and their receptors. Activation of growth factor receptors by autocrine or paracrine mechanisms has also been described in human cancers. The inhibition of stromal cells and growth A new androgen receptor antagonist A Migliaccio et al factor action by the S1 peptide may contribute to the observed strong inhibition of the xenografts growth. The peptide treatment significantly increases the number of cells undergoing apoptosis in LNCaP tumor xenografts in agreement with the view that hormonal activation of Src protects target cells from apoptosis (Singer et al., 1999; Kousteni et al., 2001) . In recent years, much evidence has shown that in multiple cell types under different experimental conditions, steroid receptors directly interact with several signaling effectors and trigger various biological effects. In addition to Src, these effectors include calmodulin (Castoria et al., 1988) , the regulatory subunit of the phosphoinositide 3-kinase, p85a (Simoncini et al., 2000; Castoria et al., 2001) , Shc (Song et al., 2002) , modulator of non genomic activity of receptor (Wong et al., 2002) , protein kinase Cz (Castoria et al., 2004) , EGF receptor (Marquez et al., 2001; Migliaccio et al., 2005) , and many other signaling or signaling-related proteins. Therefore, approaches similar to those followed in this report, that is, recognition of new receptor/signaling effector interactions and identification of new inhibitors of such interactions, could enable us to specifically inhibit different hormone actions mediated by signal transducing pathways in multiple cell types and in different pathological conditions.
Materials and methods

Constructs
The cDNA coding hAR was cloned into the pSG5 expression vector, as reported previously (Chang et al., 1988) . The hAR deletion mutants D1, D2 and D3, lacking part of the prolinerich region spanning from 372 to 386 AA, were generated using in vitro site-directed mutagenesis. The mutants D2 (D372-378) and D3 (D380-386) were constructed from the hAR using the Gene Tailor Site-direct Mutagenesis System (Invitrogen, Carlsbad, CA, USA) and the mutagenic primers 5 0 -TTTCCACTGGCTCTGGGCGGACCCCATCCCC-3 0 and 5 0 -CCCCCTCCGCCGCCTCCCCTGGAGAACCC-3 0 , respectively. The mutant D1 (D372-385) was generated from AR mutant D2, using the mutagenic primer 5 0 -CCACTGGCTCTGGGCG 
S1
Ss − S1 Ss − S1 Ss − S1 Ss − S1 Ss − Figure 6 The S1 peptide does not affect the serum-induced S phase entry of AR-positive cells and the EGF-or serum-induced DNA synthesis and the EGF-induced cytoskeletal changes of AR-negative cells. NIH3T3, LNCaP and MCF-7 cells on coverslips were made quiescent and then left untreated or treated with the following compounds: 1 pM (NIH3T3) or 10 nM (LNCaP) R1881, 20% serum, 1 nM of S1 or Ss peptide (a). AR-negative PC3 (b) or DU145 (c) cells on coverslips were made quiescent by serum starvation (0.5% serum) and then untreated or treated with the following compounds: 100 ng/ml EGF, 20% serum, 1 nM S1 or Ss peptide. After in vivo labeling with BrdU, DNA synthesis was evaluated as in Figure 2 . Data are derived from at least 500 scored cells. The results of two independent experiments have been averaged. Means and s.e.m. are shown. DU145 cells (d) on coverslips were made quiescent by serum starvation (0.1% serum) and then untreated or treated for 30 min with 100 ng/ml EGF in the absence or presence of 1 nM S1 peptide or 5 mM PP2. PP2 was added 10 min before EGF stimulation. Cells were labeled with Texas red-conjugated phalloidin and then visualized by fluorescence microscopy. BrdU, bromodeoxyuridine; EGF, epidermal growth factor.
GAAAGCTGGAGAAC-3
0 . All constructs were verified by sequencing. The 3416 construct, containing four copies of the wt slp-HRE2 (5 0 -TGG-TCAgccAGTTCT-3 0 ), was cloned in the NheI site in pTK-TATA-Luc (Verrijdt et al., 2000) .
Cell culture, transfection and transactivation assay Human mammary cancer MCF-7 cells, fast growing human prostate cancer LNCaP cells, Cos cells and low-passage mouse embryo NIH3T3 fibroblasts were grown and made quiescent as reported (Castoria et al., 1999 (Castoria et al., , 2003 Migliaccio et al., 2000) . Human prostate carcinoma-derived PC3 and DU145 cells were cultured as described (Pandini et al., 2005; Bonaccorsi et al., 2006) . Cos cells were made quiescent and transfected as reported (Migliaccio et al., 2000) , using 2 mg of purified plasmids. Twenty-four hours later, transfected cells were left unstimulated or stimulated with the indicated compounds. The androgen-stimulated transcriptional assay in Cos cells was carried out as described (Castoria et al., 2003) . For androgen-and estradiol-stimulated transcriptional analysis, LNCaP and MCF-7 cells were made quiescent and then transfected by Superfect (Qiagen, Hilden, Germany) with 4 mg of purified plasmids. Twenty-four hours later, transfected cells were left unstimulated or stimulated with the indicated compounds. Lysates were prepared and the luciferase activity was measured using a luciferase assay system (Promega, Madison, WI, USA). The results were corrected using CH110-expressed b-galactosidase activity (Amersham Bioscience, Bucks, UK). 
Mouse xenografts
Ki67 antigen and TUNEL assays in tumor specimens
At the end of the treatments, the mice were killed and tumor specimens assayed for Ki67 antigen and apoptotic index. Sections from each specimen were cut at 3-5 mm, mounted on glass and dried overnight at 371C. They were then deparaffinized in xylene, rehydrated through a graded alcohol series and washed in PBS, which was used for all the subsequent washes as well as the antibody dilution. After the staining with hematoxylin/eosin and hematoxylin/Van Gieson, the sections were analysed by light microscopy. For immunohistochemistry, tissue sections were heated two times in a microwave oven for 5 min at 700 W in citrate buffer (pH 6), and then processed with the standard streptavidin-biotin-immunoperoxidase method (DAKO Universal Kit, DAKO Corporation, Carpinteria, CA, USA). Rabbit anti-human Ki67 (DAKO) was used (at final dilution 1:100) for 1 h at room temperature. Diaminobenzidine was used as chromogen, and hematoxylin as the nuclear counterstain. For each tissue section, negative and positive controls were performed, either leaving out the primary antibody or using tissue expressing the antigen of interest. TUNEL reaction was performed using the peroxidasebased Apoptag kit (Oncor, Gaithersburg, MD, USA). TUNEL-positive cells were detected with diaminobenzidine and H 2 O 2 , according to the supplier's instructions. For each specimen, the staining pattern as well as the score of Ki67 or apoptotic cells was evaluated by scanning the entire section and estimating the number of positive cells visible for highpower field 10 Â 20.
DNA synthesis analysis and cytoskeletal changes For bromodeoxyuridine (BrdU) incorporation analysis, quiescent cells on coverslips were left unstimulated or stimulated for 24 h with the indicated compounds. After a 6 h pulse with 100 mM BrdU (Sigma, St Louis, MO, USA), BrdU incorporation was analysed as described (Castoria et The S1 peptide does not interfere in the steroid receptordependent transcriptional activity in human prostate and breast cancer-derived cells. ARE 3416 or ERE/luc constructs were transiently transfected into LNCaP (a) or MCF-7 (b) cells. Cells were made quiescent, and then left unstimulated or stimulated for 18 h with 10 nM of either R1881 or estradiol, in the absence or presence of the indicated compounds. The S1 and Ss peptides were used at 1 nM. The antiandrogen Casodex and the antiestrogen ICI were used at 10 mM. The luciferase activity was assayed, normalized using b-gal as an internal control and expressed as arbitrary units of luciferase activity.
1999) using Alexa Fluor 594-conjugated mouse monoclonal anti-BrdU antibody (Molecular Probes, Eugene, OR, USA). The coverslips were finally stained with Hoechst 33258, inverted and mounted in Mowiol (Calbiochem, CA, USA). For cytoskeletal analysis, cells on coverslips were made quiescent by serum starvation (0.1% serum) for 24 h. They were then left unstimulated or stimulated for 20 min with the indicated compounds. F-actin was visualized using Texas red-labeled phalloidin as reported (Castoria et al., 2003) . Coverslips were mounted in Mowiol (Calbiochem, Darmstadt, Germany). The fields were analysed with a DMLB fluorescent microscope (Leica) equipped with Â 40 and Â 63 objectives. Images were generated using FW4000 (Leica) software.
Uptake analysis of labeled peptides
For this analysis, exponentially growing cells were dissociated with a non-enzymatic cell dissociation medium (Sigma). About 2.5 Â 10 5 cells were plated and cultured overnight on 30 mm plates on a glass coverslips. The cells were then made quiescent. The medium was discarded, and the cells were washed with NaCl/Pi (pH 7.3). NaCl/Pi was discarded, and the cell monolayer was incubated with the S1 and the Ss peptides conjugated to 5-(6)-carboxyfluorescein succinimidyl ester (Molecular Probes). Fluorescein-conjugated peptides were dissolved in Opti-MEM and added (at 1 nM) at 371C or 41C for 30 min to the cell medium. For direct detection of fluorescein-labeled peptides, the cells were washed three times with NaCl/Pi before being processed in Vectashield mounting Lysates, immunoprecipitation and kinase assays Lysates were prepared as described previously (Migliaccio et al., 1996) , and protein concentration was measured with a Bio-Rad protein assay kit (Bio-Rad, Hercules, CA, USA). Equal amounts of cell lysates (at a protein concentration of 2 mg/ml) were immunoprecipitated with either mouse monoclonal anti-Src antibody (clone 327; Calbiochem) or rabbit polyclonal anti-Erk-2 antibody (C-14; Santa Cruz Biotechnology, Santa Cruz, CA, USA). Src and Erk-2 kinase assays were performed as described (Migliaccio et al., 1996 (Migliaccio et al., , 1998 .
Electrophoresis and immunoblotting
The electrophoresis and immunoblotting procedures were performed as described elsewhere (Migliaccio et al., 1998) . Src was revealed using the mouse monoclonal anti-Src antibody (clone 327; Calbiochem), and Erk-2 was detected using rabbit polyclonal anti-Erk-2 antibody (C14; Santa Cruz). Cyclin D1 was detected using the mouse monoclonal antibody (AM20; Zymed, San Francisco, CA, USA). The rabbit polyclonal anti-AR antibodies (either C-19 or N-20; Santa Cruz) were used to reveal AR. ERa was immunoblotted using the rabbit polyclonal anti-ER (HC-20; Santa Cruz) antibody. Immunoreactive proteins were revealed with the ECL detection system (Amersham Bioscience).
Abbreviations
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